Synchronous apoptosis in established tumors leads to the induction of adaptive immunity.
Affiliation
Targeted Therapy Group; Institute of Cancer Science; Paterson Institute for Cancer Research; Manchester University; Manchester Cancer Research Centre; Manchester Academic Health Sciences Centres; Manchester UK.Issue Date
2013-06-01
Metadata
Show full item recordAbstract
Understanding the immune response to the death of malignant cells is critical for the development of therapeutic strategies designed to stimulate the immune system against cancer. We have developed an inducible caspase-3-mediated death switch model to explore the effects of apoptosis on the host immune system, demonstrating that the synchronous apoptotic demise of established tumors can be immunogenic and elicit anticancer T-cell responses.Citation
Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. 2013, 2 (6):e24501 OncoimmunologyJournal
OncoimmunologyDOI
10.4161/onci.24501PubMed ID
23894711Type
ArticleLanguage
enISSN
2162-4011ae974a485f413a2113503eed53cd6c53
10.4161/onci.24501
Scopus Count
Collections
Related articles
- Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response.
- Authors: Melis MH, Simpson KL, Dovedi SJ, Welman A, MacFarlane M, Dive C, Honeychurch J, Illidge TM
- Issue date: 2013 May
- A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers.
- Authors: Simpson KL, Cawthorne C, Zhou C, Hodgkinson CL, Walker MJ, Trapani F, Kadirvel M, Brown G, Dawson MJ, MacFarlane M, Williams KJ, Whetton AD, Dive C
- Issue date: 2013 May 2
- Consensus guidelines for the detection of immunogenic cell death.
- Authors: Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L
- Issue date: 2014 Oct
- Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity.
- Authors: Efimova I, Catanzaro E, Van der Meeren L, Turubanova VD, Hammad H, Mishchenko TA, Vedunova MV, Fimognari C, Bachert C, Coppieters F, Lefever S, Skirtach AG, Krysko O, Krysko DV
- Issue date: 2020 Nov
- Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death.
- Authors: Nuccitelli R, McDaniel A, Anand S, Cha J, Mallon Z, Berridge JC, Uecker D
- Issue date: 2017